Skip Navigation

European Heart Journal 1988 9(2):207-214;
Copyright © 1988 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by WILHELMSEN, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WILHELMSEN, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1988 The European Society of Cardiology

Trials in coronary heart disease and hypertension with special reference to the elderly*

L. WILHELMSEN

Department of Medicine, Östra Hospital S-41685 Göteborg, Sweden

Abstract

The risks of complications like death, myocardial infarction and stroke increase continuously with increasing age. Therefore, the chances of detecting effects of treatment in trials also increase when patients get older. The relationships between different end-points change with age, e.g. the ratio between stroke and MI increases with age. However, interventions not related to the interventions under study may also increase, causing dilution of effects. The older subject may also be more vulnerable to the side-effects of treatment. Side-effects, and quality-of-life measures, which indeed may vary with age, must be properly balanced against effects on ‘hard’ end-points.

A review of trials in patients with hypertension and myocardial infarction shows that effects of various interventions have been at least as great in older as in younger patients. However, metabolic side effects such as impaired glucose metabolism, increased serum creatinine, and increased uric acid levels have not been negligible, and such effects may turn out to be more hazardous in the elderly than in younger patients. The balance between positive and negative effects must be properly assessed in relation to the prognosis of the untreated condition. Patients who have suffered a myocardial infarction have, in general, a more serious prognosis than most hypertensives, and more side-effects of treatment may therefore be accepted in patients with myocardial infarction.

Key Words: Controlled trials • coronary heart disease • hypertension • elderly


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch NeurolHome page
M. Monane, D. S. Kanter, R. J. Glynn, and J. Avorn
Variability in Length of Hospitalization for Stroke: The Role of Managed Care in an Elderly Population
Arch Neurol, September 1, 1996; 53(9): 875 - 880.
[Abstract] [PDF]

Home page
 JAMAHome page
J. H. Gurwitz, N. F. Col, and J. Avorn
The Exclusion of the Elderly and Women From Clinical Trials in Acute Myocardial Infarction
JAMA, September 16, 1992; 268(11): 1417 - 1422.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.